Kingswood Wealth Advisors LLC Acquires Shares of 21,730 Nuvation Bio Inc. $NUVB

Kingswood Wealth Advisors LLC acquired a new stake in shares of Nuvation Bio Inc. (NYSE:NUVB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,730 shares of the company’s stock, valued at approximately $42,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Nuvation Bio during the fourth quarter valued at approximately $27,000. Highline Wealth Partners LLC acquired a new stake in shares of Nuvation Bio during the 2nd quarter worth approximately $25,000. Rafferty Asset Management LLC raised its position in shares of Nuvation Bio by 30.1% during the 1st quarter. Rafferty Asset Management LLC now owns 31,652 shares of the company’s stock worth $56,000 after purchasing an additional 7,325 shares during the period. Pallas Capital Advisors LLC raised its position in shares of Nuvation Bio by 108.7% during the 2nd quarter. Pallas Capital Advisors LLC now owns 42,319 shares of the company’s stock worth $83,000 after purchasing an additional 22,040 shares during the period. Finally, Pale Fire Capital SE raised its position in shares of Nuvation Bio by 17.0% during the 1st quarter. Pale Fire Capital SE now owns 45,642 shares of the company’s stock worth $80,000 after purchasing an additional 6,642 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Stock Performance

Shares of NUVB stock opened at $3.73 on Monday. Nuvation Bio Inc. has a 12-month low of $1.54 and a 12-month high of $4.09. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.92 and a beta of 1.48. The business has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $2.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.39 and a quick ratio of 9.38.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). Nuvation Bio had a negative return on equity of 46.14% and a negative net margin of 1,413.43%.The business had revenue of $4.83 million during the quarter, compared to analyst estimates of $0.42 million. On average, equities research analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on NUVB shares. JMP Securities reiterated a “market outperform” rating and set a $6.00 price target on shares of Nuvation Bio in a research report on Wednesday, June 25th. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Nuvation Bio in a research report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on Nuvation Bio from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded Nuvation Bio from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.86.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.